---
title: "Sinopharm Group Files Director List with HKEX"
description: "Sinopharm Group Co. Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange, detailing their roles and committee memberships. The board includes Non-Executive, Executive, and Ind"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/270279547.md"
published_at: "2025-12-19T09:09:59.000Z"
---

# Sinopharm Group Files Director List with HKEX

> Sinopharm Group Co. Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange, detailing their roles and committee memberships. The board includes Non-Executive, Executive, and Independent Non-Executive Directors, with Jin Bin as Chairman. The filing reflects a broad distribution of responsibilities across governance, strategy, compliance, remuneration, and nomination functions. This information was published by Sinopharm Group via the Hong Kong Stock Exchange's Issuer Information Service.

Sinopharm Group Co. Ltd. has filed an updated list of directors and their roles with the Hong Kong Stock Exchange. The board consists of Non-Executive Directors Jin Bin (Chairman), Chen Qiyu, Zu Jing, Xing Yonggang, Ma Yue, Chen Yuqing, Wen Deyong, and Li Ying; Executive Directors Lian Wanyong (President) and Yang Binghua; and Independent Non-Executive Directors Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru. Jin Bin serves as Chairman of both the Nomination and Strategy and Investment Committees and is a member of the Legal and Compliance and ESG Committee. Chen Qiyu is a member of the Strategy and Investment Committee. Lian Wanyong is a member of both the Strategy and Investment Committee and the Legal and Compliance and ESG Committee. Li Peiyu is Chairman of the Remuneration Committee and a member of the Audit, Strategy and Investment, and Legal and Compliance and ESG Committees. Wu Tak Lung chairs the Audit Committee and is a member of the Remuneration Committee and Nomination Committee. Yu Weifeng leads the Legal and Compliance and ESG Committee and is a member of the Remuneration and Nomination Committees. Shi Shenghao is a member of the Audit, Nomination, and Strategy and Investment Committees. Chen Weiru is a member of the Nomination and Strategy and Investment Committees. Other directors also hold various committee roles, reflecting a broad distribution of responsibilities across governance, strategy, compliance, remuneration, and nomination functions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251219-11961543), on December 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [01099.HK - SINOPHARM](https://longbridge.com/en/quote/01099.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| HKEX Sees Diverse IPOs Amid AI Bubble Risk | HKEX chief executive Bonnie Chan says the Hong Kong exchange has attracted a diverse range of IPO applicants, from diffe | [Link](https://longbridge.com/en/news/277069209.md) |
| HKEX says trading in shares of Wecon Holdings will be halted with effect from 27 February | HKEX says trading in shares of Wecon Holdings will be halted with effect from 27 February | [Link](https://longbridge.com/en/news/277128432.md) |
| HKEX Announces Second Interim Dividend of HK$6.52 Per Share for 2025 | Hong Kong Exchanges and Clearing Limited (HKEX) has declared a second interim dividend of HK$6.52 per share for the fina | [Link](https://longbridge.com/en/news/276993996.md) |
| Hong Kong Exchange & Clearing Q4 Profit Climbs, Lifts Dividend | Hong Kong Exchange & Clearing Ltd. reported a 15% increase in Q4 profit, reaching HK$4.34 billion, driven by a 15% rise  | [Link](https://longbridge.com/en/news/277021779.md) |
| CLP tightens Nomination Committee mandate to bolster board governance | CLP Holdings has updated its Nomination Committee's terms of reference, effective January 1, 2025, to enhance board gove | [Link](https://longbridge.com/en/news/277134106.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.